Catalyst Pharmaceuticals (CPRX)
(Real Time Quote from BATS)
$19.89 USD
-0.02 (-0.10%)
Updated Aug 16, 2024 11:46 AM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Catalyst Pharmaceutical (CPRX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$30.14 | $38.00 | $26.00 | 51.38% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Catalyst Pharmaceutical comes to $30.14. The forecasts range from a low of $26.00 to a high of $38.00. The average price target represents an increase of 51.38% from the last closing price of $19.91.
Analyst Price Targets (7 )
Broker Rating
Catalyst Pharmaceutical currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, seven are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/CPRX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/9/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/9/2024 | Cantor Fitzgerald & Co | Charles C Duncan | Strong Buy | Strong Buy |
8/9/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
8/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/3/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
5/9/2024 | Piper Sandler | Joseph M Catanzaro | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 7 |
Average Target Price | $30.14 |
LT Growth Rate | 3.50% |
Industry | Medical - Drugs |
Industry Rank by ABR | 94 of 253 |
Current Quarter EPS Est: | 0.49 |